Reckitt Eyes Greater Slice Of China Market With R&D Center Investment

Reckitt is investing over $40m to build a dedicated Chinese R&D center of excellence in Shanghai as it looks to capitalize on the double-digit sales growth it has recorded in the world's most populous market over recent years.

• Source: Shutterstock

Reckitt is dialing up its investment in China with plans to open a global research and development center of excellence in Shanghai.

Slated to commence operations in 2026, the Shanghai center is expected to turbocharge Reckitt’s R&D activities in one of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By 

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

US Consumer Health Market People News; BodyArmor, Just Ingredients, CRN/Radicle Award

 

CRN/Radicle Science expand Trailblazer Award nominations; BodyArmor brand relaunch with ‘Choose Better’ campaign and pro athletes; and Just Ingredients catches Bryce Harper as partner.

Italy’s PharmaNutra Grows Presence In Americas And MENA

 
• By 

Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.

More from Business

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By 

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

OLLY Argues Standard Of Support For Kids Chillax Claims Casts Chill Over Supplement Advertising

 

NAD and NARB track their decisions on support for ad claims with Federal Trade Commission policies, including the requirement of RCTs to support health claims for supplements, a standard the industry argues is required for drug claims and shouldn’t be applied for dietary ingredients.